Health and Fitness Health and Fitness
Thu, December 8, 2011
[ Thu, Dec 08th 2011 ] - Market Wire
Zimmer Introduces New CLS Breviusa" Hip Stem with Kinectiv Technology in the United States
[ Thu, Dec 08th 2011 ] - Market Wire
VentriPoint Announces Proposed Issuance of Shares for Debt and Offering
[ Thu, Dec 08th 2011 ] - Market Wire
Janssen Biotech, Inc. Announces Collaborative Dev .. e Agreement for Investigational Anti-Cancer Drug,
[ Thu, Dec 08th 2011 ] - Market Wire
Insulet Corporation to Present at Upcoming Investor Conference
[ Thu, Dec 08th 2011 ] - Market Wire
Pharmacyclics Forms Pact to Develop and Commercia .. or Hematologic Cancers with Janssen Biotech, Inc.
[ Thu, Dec 08th 2011 ] - Market Wire
Transcept Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
[ Thu, Dec 08th 2011 ] - Market Wire
Highlights from BioMarin's Research & Development Day
[ Thu, Dec 08th 2011 ] - Market Wire
Universal Health Services, Inc. to Present at the Oppenheimer 22nd Annual Healthcare Conference
[ Thu, Dec 08th 2011 ] - Market Wire
Abbott Initiates Clinical Trial to Evaluate the A .. r Scaffold Compared to a Metallic Drug Eluting St
[ Thu, Dec 08th 2011 ] - Market Wire
A Change in Tides - Featured Research on Humana Inc. and Sunoco, Inc.
[ Thu, Dec 08th 2011 ] - Market Wire
NeoStem Appoints a Biopharmaceutical Business Lea .. Cellular Therapy Expert to its Board of Directors
[ Thu, Dec 08th 2011 ] - Market Wire
Radient Pharmaceuticals Submits an Abstract to the American Society of Colon and Rectal Surgeons
[ Thu, Dec 08th 2011 ] - Market Wire
Merus Labs and Envoy Update Shareholder Meeting Matters
[ Thu, Dec 08th 2011 ] - Market Wire
Lpath Files Registration Statement to Raise up to $10 Million
[ Thu, Dec 08th 2011 ] - Market Wire
Boston Scientific Receives FDA Approval for New I .. d for Precision Plusa" Spinal Cord Stimulator Sys
[ Thu, Dec 08th 2011 ] - Market Wire
China's Booming Healthcare Sector Poised to Benefit China Medical Technologies and Sinovac Biotech
[ Thu, Dec 08th 2011 ] - Market Wire
Nektar Reports Affymax Announced FDA Advisory Com .. fit/Risk Profile for Peginesatide for Treatment o
[ Thu, Dec 08th 2011 ] - Market Wire
Genomic Health Announces Positive Results of Firs .. Biomarker Discovery Using Next Generation Sequen
[ Thu, Dec 08th 2011 ] - Market Wire
Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
[ Thu, Dec 08th 2011 ] - Market Wire
WeedMaps Acquires Android Application WeedLaws
[ Thu, Dec 08th 2011 ] - Market Wire
Bionovo Announces the Publication of its Tissue S .. en Receptor Modulators for Postmenopausal Obesity
[ Thu, Dec 08th 2011 ] - Market Wire
SEQUEL Trial Results for Qnexa Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
[ Thu, Dec 08th 2011 ] - Market Wire
ImmuCell Presents Mast Out(R) Product Offering at World Animal Health Congress
[ Thu, Dec 08th 2011 ] - Market Wire
The New England Journal of Medicine Publishes Stu .. us Vaccine Demonstrates Protection Against Illnes
[ Thu, Dec 08th 2011 ] - Market Wire
Coronado Biosciences Announces Phase 1 Results of .. e Presented at the American Society of Hematology
[ Thu, Dec 08th 2011 ] - Market Wire
Shire Reports Positive Phase II Results for Inves .. nse (lisdexamfetamine dimesylate) Capsules, (CII)
[ Thu, Dec 08th 2011 ] - Market Wire
Neurologist Survey Confirms Need for Improved Adm .. ation of Parkinson's Disease Acute Rescue Therapy
[ Thu, Dec 08th 2011 ] - Market Wire
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
[ Thu, Dec 08th 2011 ] - Market Wire
Most Couples Prefer Spontaneity in the Bedroom
[ Thu, Dec 08th 2011 ] - Market Wire
Isis Pharmaceuticals Holds Webcast to Discuss Recent Additions to its Development Pipeline

Isis Pharmaceuticals Holds Webcast to Discuss Recent Additions to its Development Pipeline


Published on 2011-12-08 04:17:01 - Market Wire
  Print publication without navigation


Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Additions to its... -- CARLSBAD, Calif., Dec. 8, 2011 /PRNewswire/ --

Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Additions to its Development Pipeline

[ ]

CARLSBAD, Calif., Dec. 8, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: [ ISIS ]) announces the following webcast:

cellpadding="0" cellspacing="0" id="convertedTable" style="BORDER-BOTTOM: 1pt; BORDER-LEFT: 1pt; BORDER-COLLAPSE: collapse; BORDER-TOP: 1pt; BORDER-RIGHT: 1pt">

What:

Recent Additions to Isis' Development Pipeline   

 

When:

Thursday, December 15, 2011 at 12:00 p.m. ET / 9:00 a.m. PT                                                                

 

Where:

www.isispharm.com                             

 

How:

Live on the Internet.  Simply log onto our Web site listed above.          

 

Contacts:

Kristina Lemonidis

 

Director, Investor Relations

 

(760) 603-2490

 

 

Amy Blackley, Ph.D.

 

Assistant Director, Corporate Communications

 

(760) 603-2772

 

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 25 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

 

SOURCE Isis Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]

Contributing Sources